Skip to main content

Table 1 Laboratory parameters

From: Systemic sarcoidosis with bone marrow involvement responding to therapy with adalimumab: a case report

Point in time

Laboratory parameter

  

Therapy

Hb (mmol/L)

WBC (×109/L)

PLT (×109/L)

MCV (fL)

Glu (mmol/L)

CRP (mg/L)

Sed (mm/hour)

2 months before referral

None

5.52

 

132

    

Referral

None

4.41

2.9

163

77.3

   

Diagnosis

Nonea

4.03

3.7

191

77.4

   

Post-diagnosis (wk)

1

Pred

4.34

3.9

220

79.7

   
 

2

Pred

4.41

4.0

201

80.0

14.6

27.0

67

 

9

ADAb

5.96

2.7

142

79.5

14.3

25.0

41

 

20

ADAc

5.46

3.3

179

78.0

5.8

33.0

105

 

24

Noned

4.59

3.0

147

79.7

4.9

36.0

80

 

31

Noned

4.41

3.8

174

80.9

 

34.0

92

 

36

ADAe

4.10

3.7

152

84.3

5.9

30.0

50

 

40

ADA

4.47

3.4

170

82.6

4.2

23.0

66

 

45

ADA

5.03

3.6

177

83.4

 

9.0

63

 

49

ADA

6.02

4.2

165

80.9

4.3

6.0

63

 

53

ADA

5.96

3.7

146

77.2

 

4.0

14

 

57

ADA

6.4

4.0

122

77.5

117

4.0

47

  1. aBegan prednisone at 20 mg/day;
  2. bsecond dose of adalimumab, tapered off prednisone;
  3. c7 doses of adalimumab, completely off prednisone;
  4. dpatient discontinued adalimumab for 9 weeks; adalimumab was restarted at post-diagnosis week 33;
  5. ethree doses of second course of adalimumab.
  6. Abbreviations: ADA, adalimumab; CRP, C-reactive protein; Glu, glucose; Hb, hemoglobin; MCV, mean cell volume; PLT, platelets; Pred, prednisone; Sed, sedimentation rate; WBC, white blood cells.